JSA advised Felix Pharmaceuticals in connection with a USD 175 million investment by Advent International, a leading global private equity firm, for acquiring a significant minority stake in the company.
Founded in 2015 and headquartered in Dublin, Felix Pharmaceuticals develops and manufactures generic (off-patent) medicines for companion animals such as dogs, cats, and horses. The company boasts one of the industry’s broadest product portfolios, including 14 U.S. FDA-approved drugs, with a robust pipeline under development. Felix supplies these products under private labels and is one of the fastest-growing players in the global animal health space.
The JSA team advising Felix was led by Sidharrth Shankar (Partner), with support from Prakriti Jaiswal (Partner), Anindita Basu (Principal Associate), Rishika Agarwal (Senior Associate), Eksha Narayan (Senior Associate), and Jatin Oberoi (Senior Associate).
Prakriti specialises in mergers & cross border investments & acquisitions and private equity transactions. Her experience includes rendering advisory and structuring services on a variety of transactions including acquisitions of shares & business, private equity investments, joint ventures and corporate advisory.